EOT

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hepatology, INSERM, Immunity, Interferon, Immune system, ALT, HDV, HBsAg, AASLD, Clinical trial, Viral hepatitis, EOT, Patient, Small RNA, Abstract, Week, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, Peginterferon-alfa, CHD, APHP, Hepatitis, Vir, RNA, Vaccine, Pharmaceutical industry, Communications satellite, Treatment, Medicine

To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.

Key Points: 
  • To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.
  • “Chronic hepatitis delta is the most aggressive form of viral hepatitis.
  • Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:45 p.m. Pacific Time / 4:45 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hepatology, INSERM, Interferon, AASLD, Viral hepatitis, Patient, EOT, Abstract, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, CHD, APHP, Hepatitis, Vaccine, Treatment, Medicine, Boston

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.
  • These include one late-breaking poster presentation and one late-breaking oral presentation.
  • Title: VIR-2218 and VIR-3434 With or Without Pegylated Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results After 24 Weeks of Therapy (March Study Part B) (Abstract #48500)
    Presenter: Edward Gane, M.D., Professor of Medicine at the University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital
    Title: The Monoclonal Antibody VIR-3434 And siRNA VIR-2218 for the Treatment of Chronic Hepatitis D Virus: Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract #5004)
    Presenter: Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, and Head of Viral Hepatitis at INSERM UMR1149, France
    Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Most family business leaders are accelerating succession plans in the face of mounting pressures: KPMG poll

Retrieved on: 
Thursday, November 23, 2023
Sale, EOTS, Perception, KPMG, Update, EOT, Luigi, Head, Richard D. Wolff, Growth, Family, News, Video game, Management, Cryptocurrency

The findings reflect the views of 285 family business leaders included in the KPMG Private Enterprise™ Business Survey of 700 small- and medium-sized businesses (SMBs).

Key Points: 
  • The findings reflect the views of 285 family business leaders included in the KPMG Private Enterprise™ Business Survey of 700 small- and medium-sized businesses (SMBs).
  • Whether these family business leaders choose to sell to a third-party or pass the torch to the next generation, there are significant business and tax implications to consider at this time."
  • Some leaders support employee ownership as an alternative or complimentary approach to business ownership and succession.
  • "Along with financial factors, inadequate succession and transition strategies are the single biggest factors in the failure of family businesses," Mr. Archambault adds.

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Hepatology, Grade 2, FAS, Plasma, AASLD, Biotechnology, Vaccination, Patient, HBV, EOT, Enzyme inhibitor, Week, Liver, Health, Liver cancer, CHB, MD, Trial of the century, PPS, Seroconversion, Hepatitis, Pharmaceutical industry, Vaccine, HBsAg, Boston

DURHAM, N.C. and BEIJING, Nov. 13, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today shared three posters at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in Boston, MA, two of which were accepted as late-breakers providing new data from two Phase 2 assets, BRII-179 (VBI-2601) and BRII-835 (VIR-2218), within the chronic hepatitis B (CHB) clinical program.

Key Points: 
  • "We are pleased to share these data at The Liver Meeting that demonstrate the versatility of our HBV portfolio and critical insight in our search for a cure for HBV," said David Margolis, MD, Chief Medical Officer of Brii Bio.
  • "The important connection between HBsAg loss and antibody response provides a clear direction in further improving the functional cure rate and identifying patients who will most likely respond to curative treatments.
  • Highlights include:
    The PK characteristics of BRII-835 in patients with chronic HBV infection are generally similar to those in healthy volunteers.
  • In addition, Vir Biotechnology, Inc. ("Vir") is also investigating VIR-2218 and/or VIR-3434 for the treatment of HBV/HDV co-infection.

Saba Capital Issues Letter Sent to Chair of European Opportunities Trust Board Regarding its Opposition to the Proposed Tender Offer

Retrieved on: 
Tuesday, November 7, 2023
Finance, Consulting, Banking, Professional Services, Asset Management, NAV, EOT, Fund, Cryptocurrency, Security (finance)

For over a decade, our firm, Saba Capital, has been fighting for the interests of shareholders in closed-end funds and investment trusts.

Key Points: 
  • For over a decade, our firm, Saba Capital, has been fighting for the interests of shareholders in closed-end funds and investment trusts.
  • In our experience, when a fund proposes a modest tender offer instead of taking more significant action, it raises significant concerns.
  • This could lead to all shareholders suffering a net loss in value, even the ones who participate in the tender!
  • Accordingly, we strongly recommend that our fellow investors reject the continuation of the Fund until the size of the tender is increased.

Vodafone and Sumitomo announce brand for Economy of Things venture

Retrieved on: 
Tuesday, November 7, 2023
Internet of things, Chain-link fencing, Sumitomo Corporation, EV, HSBC, Mastercard, Research, Environment, Sumitomo Group, TCS, Ecosystem, Attitude, EOT, IBM, DAB, Economy, Cryptocurrency, Vodafone, Pairpoint Glass

LONDON, Nov. 7, 2023 /PRNewswire/ -- Vodafone and Sumitomo Corporation today unveiled Pairpoint, the new brand for their recently created venture previously known as Digital Asset Broker, which will help customers and business take advantage of the opportunities presented by the growing Economy of Things (EoT). The Economy of Things is the next evolution of connectivity in which devices can interact and trade securely. Pairpoint provides a safe environment in which these connected devices, machines and vehicles can now seamlessly and securely transact with each other without human intervention, but with the owner in full control.

Key Points: 
  • The Economy of Things is the next evolution of connectivity in which devices can interact and trade securely.
  • Jorge Bento, Pairpoint's CEO said: "We are thrilled to announce Pairpoint, an exciting new venture between Sumitomo and Vodafone.
  • We expect Pairpoint to bring more use cases to market across a diverse set of industries as the Economy of Things becomes commonplace."
  • Pairpoint is the result of €60 million shared investment, with Vodafone and Sumitomo respectively owning 80% and 20% of the new company.

EOT Signs Strategic Collaboration Agreement with AWS to Innovate Industrial Software for AI-Optimized Industrial Assets

Retrieved on: 
Monday, September 25, 2023
Software, Networks, Internet, Oil, Gas, Data Management, Mining, Minerals, Energy, Technology, Natural Resources, Artificial Intelligence, Engineering, Manufacturing, Well, Metadata, Amazon Web Services, SCADA, Internet of things, Service, EOT, Intelligence, Multimedia, Thought, SCA, Acquisition, Machine learning, Root cause analysis, AWS, Medical device, Asset management, Video game

EOT, a leading intelligent industrial software provider, today announced it signed a multi-year Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to help industrial companies unlock the promise of artificial intelligence (AI)-optimized industrial plants with a no-code cloud historian and digital twins residing exclusively on AWS.

Key Points: 
  • EOT, a leading intelligent industrial software provider, today announced it signed a multi-year Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to help industrial companies unlock the promise of artificial intelligence (AI)-optimized industrial plants with a no-code cloud historian and digital twins residing exclusively on AWS.
  • View the full release here: https://www.businesswire.com/news/home/20230925964567/en/
    EOT Signs Strategic Collaboration Agreement with AWS to Innovate Industrial Software for AI-Optimized Industrial Assets.
  • Matt Oberdorfer, Founder and CEO of EOT, shared his vision: "Our collaboration with AWS represents a commitment to an AI-enhanced future.
  • Hilcorp, a large, privately held exploration and production company in the United States, uses EOT software for operating their upstream assets.

Soho Square Exits Investment in Churchill via Sale to Employee Ownership Trust Following 3 Years of Transformational Growth

Retrieved on: 
Tuesday, August 15, 2023
Professional Services, Finance, FM, Education, Culture, EOT, Employee ownership trust, Soho Square, Sale, Public sector, EBITDA, PWC, Stuart Hamilton, Growth, Principal, SME, Portfolio management, Nightclub, Winston Churchill

Since Soho Square invested in Churchill in 2020, the business has won considerable market share and undergone a period of significant organic growth, which has seen EBITDA almost double.

Key Points: 
  • Since Soho Square invested in Churchill in 2020, the business has won considerable market share and undergone a period of significant organic growth, which has seen EBITDA almost double.
  • This above-plan growth has enabled Churchill to fully exit Soho Square from its investment after a hold period of just three years.
  • The sale is to an EOT which sees the business return to full employee ownership.
  • Soho Square and Churchill were advised by Grant Thornton (corporate finance), Shoosmith’s (legal) and PWC (financial due diligence).

Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd line Hodgkin Lymphoma

Retrieved on: 
Friday, June 16, 2023
Well, Hodgkin lymphoma, Cytokine release syndrome, CRS, Associate professor, Lymphoma, Malignancy, EOT, CHL, TT11, MD Anderson Cancer Center, International Conference on Population and Development, ASCT, Patient, Risk, University, PET/CT, Neoplasm, Therapy, CD30, ACTION, Conference, End, Safety, Bone marrow, Pharmaceutical industry, Medical imaging, Nivolumab

TT11 is currently being investigated in combination with Nivolumab in Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients after frontline therapy failure (NCT05352828).

Key Points: 
  • TT11 is currently being investigated in combination with Nivolumab in Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients after frontline therapy failure (NCT05352828).
  • Study protocol involves patients being treated with 2 cycles of Nivolumab, followed by a single infusion of CD30.CAR-T preceded by lymphodepletion (LD) chemotherapy.
  • A total of 15 patients were enrolled of which 13 were treated with Nivolumab + CD30 CAR-T therapy.
  • These results offer the potential to re-define Hodgkin lymphoma treatment paradigm, offering a second line treatment alternative free of transplant and high dose chemotherapy to patients who fail frontline therapy,” said Thomas Willemsen, President and CEO, Tessa Therapeutics.

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Retrieved on: 
Tuesday, June 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hodgkin lymphoma, Doxorubicin, Inc., Febrile neutropenia, Brentuximab vedotin, Vinblastine, PML, Takeda, Progression-free survival, European Hematology Association, ICML, Lymphoma, Survival, Aes, Trae tha Truth, EOT, Bleomycin, Toxicity, ADCETRIS, CHL, PFS, Diabetic neuropathy, Research and development, Dacarbazine, Congress, Development, Hair, International Conference on Population and Development, MD, Patient, Risk, Progressive multifocal leukoencephalopathy, BEACOPP, CR, Nausea, Hospital, PD-1, Massachusetts General Hospital, Death, Conference, ORR, Safety, Fatigue, Nivolumab, Pharmaceutical industry, Vaccine, Birth control, Part, Seagen

Data results will be presented at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland June 13-17.

Key Points: 
  • Data results will be presented at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland June 13-17.
  • The study will be presented on June 17, 2023.
  • Immune-mediated AEs observed to date are consistent with the individual safety profile of nivolumab.
  • Please see Important Safety Information, including a BOXED WARNING for progressive multifocal leukoencephalopathy (PML), for ADCETRIS below.